Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10966179 | Vaccine | 2013 | 6 Pages |
Abstract
This was a randomized feasibility study of a single priming NeisVac-C® vaccine dose administered at 4 or 6 months of age, compared to the currently licensed two dose priming at 2 and 4 months of age, followed by a booster vaccination at 12-13 months of age. High seroprotection rates and serum bactericidal antibody (rSBA) titers were observed in all study groups, whether a single or two dose priming vaccination was administered, at all time points investigated: one month after the priming vaccination(s) (>99% of subjects rSBA â¥Â 8), prior to booster vaccination (>65% of subjects with rSBA â¥Â 8, with the lowest titers and GMTs seen in the two dose priming group), as well as after booster vaccination administration (99% with rSBA â¥Â 128 in all three study groups, with the highest GMT of 2472 seen in the 4 month single dose group). This study confirmed trends seen in previous reports that a single-dose priming vaccination at 4 or 6 months of age can be considered a valuable alternative to the currently licensed two-dose priming vaccination schedule.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Eva-Maria Poellabauer, Borislava G. Pavlova, Sandor Fritsch, Julia Singer, Christian Neubauer, Jennifer Doralt, Barbara Valenta-Singer, Hartmut J. Ehrlich,